Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Acceleron Pharma, a biopharmaceutical company involved in the development of regenerative therapeutics, has initiated a phase I clinical trial of ACE-011, a novel treatment for bone loss disease, particularly osteoporosis.
Subscribe to our email newsletter
Acceleron said it will start the first regenerative therapeutic to enter human clinical trials from Acceleron's scientific platform that utilizes the body's own naturally-occurring growth factors.
“Based on extensive evidence from preclinical studies, ACE-011 has the potential to rebuild bone even after substantial bone loss has already occurred. The preclinical data strongly suggests that ACE-011 could fundamentally change the treatment of bone loss,” said Dr Jasbir Seehra, chief scientific officer and a founder of Acceleron.
Acceleron is conducting the phase I study in healthy post-menopausal women. The study is a randomized, placebo-controlled, a single ascending dose study designed to evaluate safety, tolerability, and pharmacology properties of ACE-011.
Following the phase I study of ACE-011, Acceleron will introduce other regenerative drug candidates into clinical development and will continue to build integrated pharmaceutical capabilities to develop these candidates into new therapies.